|14th September 2020||Target N V Biotech||200,000||Open or private purchase||$11.69||$2,338,680.00|
|11th September 2020||Target N V Biotech||199,029||Open or private purchase||$11.33||$2,255,117.99|
|8th July 2020||Target N V Biotech||25,000||Open or private purchase||$13.21||$330,177.50|
|28th May 2020||Daniel Janney||6,106||Grant/award etc.||$0.00|
|28th May 2020||Alan Fuhrman||1,221||Grant/award etc.||$0.00|
|28th May 2020||Antonio M Jr Md D Phil Gotto||6,106||Grant/award etc.||$0.00|
|28th May 2020||Jeffrey Berkowitz||6,106||Grant/award etc.||$0.00|
|28th May 2020||Mark E Mcgovern||6,106||Grant/award etc.||$0.00|
|28th May 2020||Nicole Vitullo||6,106||Grant/award etc.||$0.00|
|28th May 2020||Jay Shepard||6,106||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia.